AVECHO BIOTECHNOLOGY LIMITED — Director's Dealing 2011

Nov 27, 2011

==> picture [107 x 80] intentionally omitted <==

Company Announcement

25 November 2011

Appendix 3Y - Change of Director’s Interest Notices (3)

Dr Sandra Webb Mr J L Addison Mr D I Clarke

Attached for release to the market are (3) Appendix 3Y Notices advising of an increase in the entitlement of Dr Sandra Webb, Mr Jonathon L Addison and Mr Don I Clarke to the Company’s ordinary fully paid shares.

Such change in interest arising from the participation, as eligible shareholders, in the Share Purchase Plan offering shareholders of Phosphagenics Limited as at the Record Date of 20 October 2011 and as announced on 21 October 2011 at an issue price of $0.14 a share.

ENDS

Enquiries: David Segal Phosphagenics Limited +61 3 9565 1103

About Phosphagenics

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

Phosphagenics’ shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com www.elixia.com.au

Phosphagenics Limited ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168 PO Box 1415, Clayton South MDC VIC 3169 Australia Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151 Web: www.phosphagenics.com Email: info@phosphagenics.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PHOSPHAGENICS LIMITED ABN 32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	WEBB, Sandra Natalie
Date of last notice	24 August 2010 (3X)

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	REFER ANNEXURE “A”
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	REFER ANNEXURE “A”
Date of change	REFER ANNEXURE “A”
No. of securities held prior to change	REFER ANNEXURE “A”
Class	REFER ANNEXURE “A”
Number acquired	REFER ANNEXURE “A”
Number disposed	REFER ANNEXURE “A”
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	REFER ANNEXURE “A”
No. of securities held after change	REFER ANNEXURE “A”
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	REFER ANNEXURE “A”

REFER ANNEXURE “A”

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	REFER ANNEXURE “A”
Nature of interest	REFER ANNEXURE “A”
Name of registered holder (if issued securities)	REFER ANNEXURE “A”
Date of change	REFER ANNEXURE “A”
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	REFER ANNEXURE “A”
Interest acquired	REFER ANNEXURE “A”
Interest disposed	REFER ANNEXURE “A”
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	REFER ANNEXURE “A”
Interest after change	REFER ANNEXURE “A”

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	NOT APPLICABLE
If prior written clearance was provided, on what date was this provided?	NOT APPLICABLE

p\asx\3y sw 25 11 11

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

ANNEXURE “A” APPENDIX 3Y 25 November 2011

Schedule of Director’s Interest

DIRECTOR : WEBB, Sandra Nathalie

	PREVIOUS APPENDIX 3X 24 08 10 ASX Code : POH PRESENT APPENDIX 3Y 25 11 11 CHANGES
Director’s interest in Phosphagenics Limited shares at the time of appointment and held in name of: 1 SELF 2 Sandra N Webb & Associates P/L 3 Joyend Pty Ltd 4 Webb Family Super Fund Pty Ltd 5 TOTAL DIRECTOR’S INTEREST 6 Phosphagenics Limited – Number of Shares on Issue 7 TOTAL DIRECTORS INTEREST AS PERCENTAGE	20,000 20,000 nil 70,000 70,000 nil 15,000 15,000 nil 5,000 6,000 1,000
	110,000 111,000 1,000
	739,696,509 967,565,957 0.01485% 0.0115%

COMMENT:

Dr Webb has an interest in the above ordinary fully paid Phosphagenics Limited shares for the following reasons:

• 1 Self – Dr Webb is legally and beneficially entitled to the 20,000 shares registered in her name.

• 2 Sandra N Webb & Associates Pty Ltd – Dr Webb is the sole director of this Pty Ltd company and a beneficiary under the S N Webb Investments S/F A/c.

• 3 Joyend Pty Ltd – Dr Webb is a beneficiary under the Joyend Super Fund a/c

• 4 Webb Family Super Fund Pty Ltd- Dr Webb is a beneficiary under the Webb Family Super Fund.

Movements

Webb Family Super Fund Pty Ltd – participated in the Share Purchase Plan offering of Phosphagenics Limited as announced on 21 October 2011 and, after scale back, acquired 1,000 new ordinary fully paid Shares at $0.14 a share.

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PHOSPHAGENICS LIMITED ABN 32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	ADDISON, Jonathan Lancelot
Date of last notice	28 April 2007 (3Y)

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	REFER ANNEXURE “A”
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	REFER ANNEXURE “A”
Date of change	REFER ANNEXURE “A”
No. of securities held prior to change	REFER ANNEXURE “A”
Class	REFER ANNEXURE “A”
Number acquired	REFER ANNEXURE “A”
Number disposed	REFER ANNEXURE “A”
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	REFER ANNEXURE “A”
No. of securities held after change	REFER ANNEXURE “A”
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	REFER ANNEXURE “A”

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	REFER ANNEXURE “A”
Nature of interest	REFER ANNEXURE “A”
Name of registered holder (if issued securities)	REFER ANNEXURE “A”
Date of change	REFER ANNEXURE “A”
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	REFER ANNEXURE “A”
Interest acquired	REFER ANNEXURE “A”
Interest disposed	REFER ANNEXURE “A”
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	REFER ANNEXURE “A”
Interest after change	REFER ANNEXURE “A”

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	NOT APPLICABLE
If prior written clearance was provided, on what date was this provided?	NOT APPLICABLE

p\asx\3y ja 25 11 11

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

ANNEXURE “A” APPENDIX 3Y 25 November 2011

Schedule of Director’s Interest

DIRECTOR : ADDISON, Jonathan Lancelot

	PRESENT APPENDIX 3Y 25 11 11 ASX Code : POH PREVIOUS APPENDIX 3Y 27 04 07 CHANGES
Director’s interest in Phosphagenics Limited shares at the time of appointment and held in name of: 1 SELF 2 Perpetual Custodians Limited 3 TOTAL DIRECTOR’S INTEREST 4 Phosphagenics Limited – Number of Shares on Issue 5 TOTAL DIRECTORS INTEREST AS PERCENTAGE	Nil Nil nil 22,473 19,000 3,473
	22,473 19,000
	967,565,957 603,439,181 0.0023% 0.003%

COMMENT:

Mr Addison has an interest in the above ordinary fully paid Phosphagenics Limited shares for the following reasons:

• 1 Self – No change

• 2 Perpetual Custodians Limited – Perpetual Custodians Limited holds the shares registered in its name as custodian for the Twiga Superannuation Fund which is a fund in which Mr Addison is a beneficiary.

Movements in Entitlements

Perpetual Custodians Limited

Balance 27 05 2007 19,000 shares Acquired, as an eligible shareholder, through the Share Purchase Plan 3,473 shares offering to shareholders in Phosphagenics Limited as announced on 20 October 23011 at A$0.14 a share Balance, per Appendix 3Y, 25 11 11 22,473 shares p\asx\3y ja 25 11 11

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PHOSPHAGENICS LIMITED ABN 32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	CLARKE, Donald Ian
Date of last notice	24 August 2010 (3X)

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	REFER ANNEXURE “A”
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	REFER ANNEXURE “A”
Date of change	REFER ANNEXURE “A”
No. of securities held prior to change	REFER ANNEXURE “A”
Class	REFER ANNEXURE “A”
Number acquired	REFER ANNEXURE “A”
Number disposed	REFER ANNEXURE “A”
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	REFER ANNEXURE “A”
No. of securities held after change	REFER ANNEXURE “A”
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	REFER ANNEXURE “A”

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	REFER ANNEXURE “A”
Nature of interest	REFER ANNEXURE “A”
Name of registered holder (if issued securities)	REFER ANNEXURE “A”
Date of change	REFER ANNEXURE “A”
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	REFER ANNEXURE “A”
Interest acquired	REFER ANNEXURE “A”
Interest disposed	REFER ANNEXURE “A”
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	REFER ANNEXURE “A”
Interest after change	REFER ANNEXURE “A”

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	NOT APPLICABLE
If prior written clearance was provided, on what date was this provided?	NOT APPLICABLE

p\asx\3y dc 24 11 11

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

ANNEXURE “A” APPENDIX 3Y

25 November 2011

Schedule of Director’s Interest

DIRECTOR : CLARKE, Donald Ian

	PREVIOUS APPENDIX 3X 24 08 10 ASX Code : POH PRESENT APPENDIX 3Y 25 11 11 CHANGES
Director’s interest in Phosphagenics Limited shares at the time of appointment and held in name of: 1 SELF 2 Soldon Investments Pty ltd 3 TOTAL DIRECTOR’S INTEREST 4 Phosphagenics Limited – Number of Shares on Issue 7 TOTAL DIRECTORS INTEREST AS PERCENTAGE	nil nil 30,000 35,484 5,484
	30,000 35,484 5,484
	739,696,509 967,565,957 0.0041% 0.0037%

COMMENT:

Soldon Investments Pty Ltd is the trustee for The Clarke Family Superannuation Fund (“Fund”).

Mr Clarke is a director of Soldon Investments Pty Ltd and is a beneficiary under the Fund.

Movements

Soldon Investments Pty Ltd – participated, as an eligible shareholder, in the Share Purchase Plan offering by Phosphagenics, as announced on 21 October 2011 and, after scale-back, acquired 5,484 new ordinary fully paid shares at $0.14 a share.

p\asx\3y dc 25 11 11